Last update Feb. 5, 2022

Toremifene Citrate

Very High Risk

Very unsafe. Contraindicated. Use of an alternative or cessation of breastfeeding. Read the Comment.

Non-steroidal derivative of triphenylethylene that binds to estrogen receptors and has potent anti-estrogenic properties, similar to those of tamoxifen. It is used as antineoplastic hormonal therapy in the treatment of hormone-dependent metastatic breast cancer in post-menopausal patients. Oral administration.

At the date of the last update, there was no published data available on its excretion in human milk.

Although its pharmacokinetic data (large volume of distribution, moderately high molecular weight and very high percentage of protein binding) make it unlikely for it to pass into the mothers’ milk in a clinically significant quantity, its long elimination half-life (EMA 2006) could favor it.

Breastfeeding is practically impossible, since before breastfeeding again after the last administration of toremifene, it would be necessary to wait 5 half-lives (25 days) for 97% of it to be eliminated from the body. Meanwhile, the milk would have to be expressed and discarded regularly to maintain production.

Alternatives

We do not have alternatives for Toremifene Citrate.

Suggestions made at e-lactancia are done by APILAM team of health professionals, and are based on updated scientific publications. It is not intended to replace the relationship you have with your doctor but to compound it. The pharmaceutical industry contraindicates breastfeeding, mistakenly and without scientific reasons, in most of the drug data sheets.

Jose Maria Paricio, Founder & President of APILAM/e-Lactancia

Your contribution is essential for this service to continue to exist. We need the generosity of people like you who believe in the benefits of breastfeeding.

Thank you for helping to protect and promote breastfeeding.

José María Paricio, founder of e-lactancia.

Other names

Toremifene Citrate in other languages or writings:

Group

Toremifene Citrate belongs to this group or family:

Tradenames

Main tradenames from several countries containing Toremifene Citrate in its composition:

Pharmacokinetics

Variable Value Unit
Oral Bioavail. 100 %
Molecular weight 406 daltons
Protein Binding 98 %
VD 8.3 l/Kg
Tmax 3 (2-5) hours
120 hours

References

  1. EMA. Fareston (Toremifeno). Ficha técnica 2006 Full text (in our servers)
  2. EMA. Fareston (Toremifeno). Drug Summary. 2006 Full text (in our servers)

Total visits

2,050

Help us improve this entry

How to cite this entry

Do you need more information or did not found what you were looking for?

   Write us at elactancia.org@gmail.com

e-lactancia is a resource recommended by Asociación Española de Bancos de Leche Humana of Spain

Would you like to recommend the use of e-lactancia? Write to us at corporate mail of APILAM